Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Glycorex Transplantation AB's
Operating Income
for the
three
months ended in Mar. 2026 was €-0.32 Mil. Glycorex Transplantation AB's Interest Expense for the
three
months ended in Mar. 2026 was €-0.01 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Glycorex Transplantation AB's Interest Coverage or its related term are showing as below:
FRA:O33's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025 * Ranked among companies with meaningful Interest Coverage only.
Glycorex Transplantation AB (FRA:O33) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Glycorex Transplantation AB Interest Coverage Related Terms
Glycorex Transplantation AB Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Glycorex Transplantation AB Interest Coverage Chart
FRA:O33 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, Glycorex Transplantation AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's Interest Coverage falls into.
Glycorex Transplantation AB Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Glycorex Transplantation AB did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Glycorex Transplantation AB (FRA:O33) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Glycorex Transplantation AB and its competitors. According to the industry distribution chart, Glycorex Transplantation AB ranks #999999 out of 374 companies in the Biotechnology industry.
Is Glycorex Transplantation AB's Interest Coverage too high?
Glycorex Transplantation AB's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Glycorex Transplantation AB ranks #999999 out of 374 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #999999 out of 374 companies for Interest Coverage. This places Glycorex Transplantation AB in the lower half of its industry. The industry median Interest Coverage is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 374 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Glycorex Transplantation AB and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glycorex Transplantation AB's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (FRA:O33) is currently considered Possible Value Trap. The stock's GF Value™ is €0.14, compared to a current price of €0.09 — trading 36.7% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Glycorex Transplantation AB (FRA:O33), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (FRA:O33) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of €0.09 is trading 36.7% below its estimated GF Value™ of €0.14.
GuruFocus considers Glycorex Transplantation AB to be Possible Value Trap.
Key valuation signals for FRA:O33:
Interest Coverage: 0 (At Loss)
GF Value™: €0.14 vs. price of €0.09 (36.7% below fair value)
No single metric tells the full story. See the FRA:O33 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for FRA:O33
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O33 has been successfully added to your 
